Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 291

1.

Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.

Guzzetta NA, Russell IA, Williams GD.

Anesth Analg. 2012 Aug;115(2):364-78. doi: 10.1213/ANE.0b013e31825aff10. Epub 2012 May 31. Review.

PMID:
22652310
2.

Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Pychyńska-Pokorska M, Pągowska-Klimek I, Krajewski W, Moll JJ.

J Cardiothorac Vasc Anesth. 2011 Dec;25(6):987-94. doi: 10.1053/j.jvca.2011.05.012. Epub 2011 Aug 11.

PMID:
21835642
3.

The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference.

Karkouti K, Beattie WS, Crowther MA, Callum JL, Chun R, Fremes SE, Lemieux J, McAlister VC, Muirhead BD, Murkin JM, Nathan HJ, Wong BI, Yau TM, Yeo EL, Hall RI.

Can J Anaesth. 2007 Jul;54(7):573-82. Review.

PMID:
17602044
4.

Is recombinant activated factor VII effective in the treatment of excessive bleeding after paediatric cardiac surgery?

Okonta KE, Edwin F, Falase B.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):690-4. Epub 2012 Jul 18. Review.

5.

Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011.

Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C, Koster A, Mackenzie GS, Murphy GJ, Spiess B, Ad N.

Innovations (Phila). 2012 Jul-Aug;7(4):229-41. doi: 10.1097/IMI.0b013e3182747699.

PMID:
23123988
6.

Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry.

Dunkley S, Phillips L, McCall P, Brereton J, Lindeman R, Jankelowitz G, Cameron P.

Ann Thorac Surg. 2008 Mar;85(3):836-44. doi: 10.1016/j.athoracsur.2007.06.076.

PMID:
18291152
7.

The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Pychyńska-Pokorska M, Moll JJ, Krajewski W, Jarosik P.

Pediatr Crit Care Med. 2004 May;5(3):246-50.

PMID:
15115562
8.

Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: an observational study of practices in 23 French cardiac centres (2005-7).

Hacquard M, Durand M, Lecompte T, Boini S, Briançon S, Carteaux JP.

Eur J Cardiothorac Surg. 2011 Dec;40(6):1320-7. doi: 10.1016/j.ejcts.2011.03.032. Epub 2011 May 6.

PMID:
21550261
9.

Recombinant factor VIIa (NovoSeven) as a hemostatic agent after surgery for congenital heart disease.

Razon Y, Erez E, Vidne B, Birk E, Katz J, Tamari H, Dagan O.

Paediatr Anaesth. 2005 Mar;15(3):235-40.

PMID:
15725322
10.

Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.

Schmid P, Mordasini A, Luginbühl M, Regli B, Kohler HP, Zimmermann H, Inderbitzin D, Hirt A, Lämmle B, Alberio L.

Swiss Med Wkly. 2011 Jul 7;141:w13213. doi: 10.4414/smw.2011.13213.

11.

Safety of recombinant activated factor VII in randomized clinical trials.

Levi M, Levy JH, Andersen HF, Truloff D.

N Engl J Med. 2010 Nov 4;363(19):1791-800. doi: 10.1056/NEJMoa1006221. Erratum in: N Engl J Med. 2011 Nov 17;365(20):1944.

12.

An evaluation of eptacog alfa in nonhaemophiliac conditions.

Mallarkey G, Brighton T, Thomson A, Kaye K, Seale P, Gazarian M.

Drugs. 2008;68(12):1665-89. Review.

PMID:
18681490
13.

Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.

Isbister J, Phillips L, Dunkley S, Jankelowitz G, McNeil J, Cameron P.

Intern Med J. 2008 Mar;38(3):156-65. Epub 2007 Oct 3.

PMID:
17916172
15.

Effective management of refractory postcardiotomy bleeding with the use of recombinant activated factor VII.

Filsoufi F, Castillo JG, Rahmanian PB, Scurlock C, Fischer G, Adams DH.

Ann Thorac Surg. 2006 Nov;82(5):1779-83.

PMID:
17062247
16.

Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.

Tatoulis J, Theodore S, Meswani M, Wynne R, Hon-Yap C, Powar N.

Interact Cardiovasc Thorac Surg. 2009 Sep;9(3):459-62. doi: 10.1510/icvts.2009.204735. Epub 2009 Jun 18.

17.

Efficacy and safety of activated recombinant factor VII in cardiac surgical patients.

Hardy JF, Bélisle S, Van der Linden P.

Curr Opin Anaesthesiol. 2009 Feb;22(1):95-9. doi: 10.1097/ACO.0b013e32831a40a3. Review.

PMID:
19295298
18.

Administration of recombinant activated factor VII in the intensive care unit after complex cardiovascular surgery: clinical and economic outcomes.

Uber WE, Toole JM, Stroud MR, Haney JS, Lazarchick J, Crawford FA Jr, Ikonomidis JS.

J Thorac Cardiovasc Surg. 2011 Jun;141(6):1469-77.e2. doi: 10.1016/j.jtcvs.2011.02.033. Epub 2011 Mar 31.

19.

Defining the role of recombinant activated factor VII in pediatric cardiac surgery: where should we go from here?

Warren OJ, Rogers PL, Watret AL, de Wit KL, Darzi AW, Gill R, Athanasiou T.

Pediatr Crit Care Med. 2009 Sep;10(5):572-82. doi: 10.1097/PCC.0b013e3181a642d5. Review.

PMID:
19451849
20.

No evidence or no alternative? Taking responsibility for off-label prescribing.

Ghinea N, Lipworth W, Kerridge I, Day R.

Intern Med J. 2012 Mar;42(3):247-51. doi: 10.1111/j.1445-5994.2012.02713.x.

PMID:
22432984
Items per page

Supplemental Content

Write to the Help Desk